Search results for "High flow nasal cannula"

showing 8 items of 8 documents

High flow nasal therapy in immunocompromised patients with acute respiratory failure: A systematic review and meta-analysis.

2019

Abstract Purpose The role of high-flow nasal therapy (HFNT) as compared to conventional oxygen therapy (COT) in immunocompromised patients admitted to intensive care unit (ICU) with acute respiratory failure (ARF) remains unclear. We conducted a systematic review and meta-analysis in order to address this issue. Methods We searched PubMed, Medline and Embase until November 7th, 2018. Randomized controlled trials (RCTs), non-randomized prospective and retrospective evidence were selected. Observational studies were considered for sensitivity analysis. Primary outcome was mortality rate; intubation rate was a secondary outcome. Results We included four studies in the primary analysis: one RCT…

medicine.medical_specialtyCritical CareAcute respiratory failure High flow nasal cannula High flow nasal therapy Immunocompromised patients Mechanical ventilation Noninvasive ventilation Oxygen therapy Cannula Humans Immunocompromised Host Intubation Intratracheal Noninvasive Ventilation Oxygen Inhalation Therapy Randomized Controlled Trials as Topic Respiratory Distress Syndrome Adult Critical Caremedicine.medical_treatmentAcute respiratory failureCritical Care and Intensive Care Medicinelaw.inventionImmunocompromised Host03 medical and health sciencesMechanical ventilation0302 clinical medicineRandomized controlled triallawInternal medicineOxygen therapyIntubation IntratrachealImmunocompromised patientmedicineCannulaHumansIntubationHigh flow nasal therapyRandomized Controlled Trials as TopicRespiratory Distress Syndromebusiness.industryMortality rateOxygen Inhalation Therapy030208 emergency & critical care medicineRetrospective cohort studyOdds ratioOxygen therapyIntensive care unitHigh flow nasal cannula030228 respiratory systemMeta-analysisbusinessNoninvasive ventilation
researchProduct

High Flow Nasal Therapy Use in Patients with Acute Exacerbation of COPD and Bronchiectasis: A Feasibility Study

2020

The efficacy and feasibility of high flow nasal therapy (HFNT) use in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and bronchiectasis is unknown. We performed a single-center, single-arm prospective observational study in patients with AECOPD, documented bronchiectasis, pH >= 7.35, respiratory rate (RR) >= 26 breaths/minute despite receiving maximal medical treatment and oxygen via face mask up to 10 L/m. Patients received HFNT (Airvo 2, Fisher & Paykel) at a gas flow of 50 L/min and FIO2 adjusted to maintain SpO(2) >= 92%. Dyspnea, rated by Borg scale, RR, arterial blood gases and mucus production (ranging from 1 to 3) were collected befor…

Pulmonary and Respiratory MedicineMaleAcute exacerbation of chronic obstructive pulmonary diseasemedicine.medical_specialtyExacerbationbronchiectasishumidification03 medical and health sciencesPulmonary Disease Chronic Obstructivebronchiectasi0302 clinical medicineacute respiratory failure bronchiectasis COPD High flow nasal cannula humidification mucus plug sputumRespiratory RateInternal medicineMedicineCannulaHumansCOPDIn patientAcute respiratory failure030212 general & internal medicineProspective StudiesAgedCOPDBronchiectasisacute respiratory failurebusiness.industryOxygen Inhalation TherapysputumCarbon Dioxidemedicine.diseaseSymptom Flare UpHigh flow nasal cannulaMucusDyspnea030228 respiratory systemmucus plugSputumFeasibility StudiesFemalemedicine.symptomBlood Gas AnalysisbusinessHigh flow
researchProduct

High flow nasal therapy versus noninvasive ventilation as initial ventilatory strategy in COPD exacerbation: a multicenter non-inferiority randomized…

2020

Abstract Background The efficacy and safety of high flow nasal therapy (HFNT) in patients with acute hypercapnic exacerbation of chronic obstructive pulmonary disease (AECOPD) are unclear. Our aim was to evaluate the short-term effect of HFNT versus NIV in patients with mild-to-moderate AECOPD, with the hypothesis that HFNT is non-inferior to NIV on CO2 clearance after 2 h of treatment. Methods We performed a multicenter, non-inferiority randomized trial comparing HFNT and noninvasive ventilation (NIV) in nine centers in Italy. Patients were eligible if presented with mild-to-moderate AECOPD (arterial pH 7.25–7.35, PaCO2 ≥ 55 mmHg before ventilator support). Primary endpoint was the mean di…

MaleExacerbationEquivalence Trials as TopicCritical Care and Intensive Care MedicineAcute respiratory failurelaw.invention03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineRandomized controlled triallawClinical endpointmedicineHumansCannulaAcute respiratory failure; Chronic obstructive pulmonary disease; High flow nasal cannula; High flow nasal therapy; Noninvasive ventilation030212 general & internal medicineHigh flow nasal therapyAgedCOPDbusiness.industryResearchhigh flow oxygen therapy high flow nasal cannula noninvasive ventilation COPD carbon dioxide acute respiratory failureChronic obstructive pulmonary diseaselcsh:Medical emergencies. Critical care. Intensive care. First aidOxygen Inhalation Therapylcsh:RC86-88.9Middle Agedmedicine.diseaseSymptom Flare UpConfidence intervalHigh flow nasal cannula030228 respiratory systemItalyAnesthesiaBreathingNoninvasive ventilationFemaleHigh flowbusinessNoninvasive ventilationHuman
researchProduct

Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases.

2021

Patients with pre-existing respiratory diseases in the setting of COVID-19 may have a greater risk of severe complications and even death.A retrospective, multicenter, cohort study with 5847 COVID-19 patients admitted to hospitals. Patients were separated in two groups, with/without previous lung disease. Evaluation of factors associated with survival and secondary composite end-point such as ICU admission and respiratory support, were explored.1,271 patients (22%) had a previous lung disease, mostly COPD. All-cause mortality occurred in 376 patients with lung disease (29.5%) and in 819 patients without (17.9%) (Previous lung disease is a risk factor for mortality in patients with COVID-19.…

HOPE-COVID-19 Health Outcome Predictive Evaluation for COVID-19Respiratory diseasesOriginal30-Day mortalityenfermedades respiratoriasACE2 angiotensin converting enzyme IIlaw.invention0302 clinical medicineCQ/HCQ chloroquine/hydroxychloroquinelawCOPDrespiratory diseasesPrognosisICU intensive care unitIntensive care unitSTROBE strengthening the reporting of observational studies in epidemiologypronósticomedicine.anatomical_structureEPOCCohort studyPulmonary and Respiratory Medicinemedicine.medical_specialty30-day mortalityRT-PCR real time reverse transcriptase-polymerase chain reactionSARS-CoV-2 severe acute respiratory syndrome coronavirus 2WHO World Health OrganizationMERS middle east respiratory syndrome03 medical and health sciencesInternal medicinemedicineCOPDCOVID-19 2019 novel coronavirusRisk factorIQR interquartile rangeLungmortalidad a 30 díasbusiness.industryFEV1 forced expiratory volume in one secondCOVID-19Retrospective cohort studymedicine.diseaseHR hazard ratioICS inhaled corticosteroidsCI confidence intervalCoronavirusCOPD chronic obstructive pulmonary disease030228 respiratory systemRespiratory failureILD interstitial lung diseaseMiddle East respiratory syndromeprognosisHFNC high flow nasal cannulabusiness
researchProduct

Accuracy of Nasal Pressure Swing to Predict Failure of High-Flow Nasal Oxygen in Patients with Acute Hypoxemic Respiratory Failure

2023

In a real-life cohort of patients with AHRF undergoing HFNO, ΔPnose showed excellent accuracy in predicting early failure, similar of that displayed by ROX. Giving that the decision to upgrade to NIV or MV was based on clinical variables, the high accuracy of ROX in predicting failure of HFNO is not surprising. The similar accuracy of ΔPnose (the only measurement that remained blinded to our clinical decision), strengthened the association with outcome, avoiding incorporation bias.

Pulmonary and Respiratory Medicineself-inflicted lung injuryacute respiratory failurenon-invasive mechanical ventilationhigh flow nasal cannulaesophageal pressure swingshigh flow nasal cannulaacute respiratory failure high flow nasal cannula non-invasive mechanical ventilation esophageal pressure swings nasal pressure swings respiratory monitoring inspiratory effort self-inflicted lung injurynasal pressure swingsCritical Care and Intensive Care MedicineAcute respiratory failurerespiratory monitoringinspiratory effort
researchProduct

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a …

2022

Invasive mechanical ventilation; COVID-19; Critical care Ventilación mecánica invasiva; COVID-19; Cuidado crítico Ventilació mecànica invasiva; COVID-19; Atenció crítica Background Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods This is a multin…

:enfermedades respiratorias::trastornos respiratorios::insuficiencia respiratoria [ENFERMEDADES]COVID-19; Critical care; High flow nasal cannula; Invasive mechanical ventilationRespiració artificialCritical Care and Intensive Care Medicine[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractCOVID-19 (Malaltia) - Tractament[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCOVID-19; Critical care; High flow nasal cannula; Invasive mechanical ventilation; Humans; Prospective Studies; SARS-CoV-2; Tachypnea; COVID-19; Respiratory Insufficiency:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]HumansProspective StudiesInvasive mechanical ventilation:Otros calificadores::/terapia [Otros calificadores]TachypneaInsuficiència respiratòria - TractamentSARS-CoV-2:Therapeutics::Therapeutics::Respiratory Therapy::Respiration Artificial::Noninvasive Ventilation [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]COVID-19:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:Other subheadings::/therapy [Other subheadings]:terapéutica::terapéutica::terapia respiratoria::respiración artificial::ventilación no invasiva [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]:Respiratory Tract Diseases::Respiration Disorders::Respiratory Insufficiency [DISEASES]High flow nasal cannulaProspective StudieCritical careRespiratory InsufficiencyHumanCritical Care
researchProduct

Ventilatory associated barotrauma in COVID-19 patients: A multicenter observational case control study (COVI-MIX-study)

2022

Background The risk of barotrauma associated with different types of ventilatory support is unclear in COVID- 19 patients. The primary aim of this study was to evaluate the effect of the different respiratory support strategies on barotrauma occurrence; we also sought to determine the frequency of barotrauma and the clinical characteristics of the patients who experienced this complication. Methods This multicentre retrospective case-control study from 1 March 2020 to 28 February 2021 included COVID-19 patients who experienced barotrauma during hospital stay. They were matched with controls in a 1:1 ratio for the same admission period in the same ward of treatment. Univariable and multivari…

Pulmonary and Respiratory MedicineHigh flow nasal cannulaAcute respiratory failure; Barotrauma; COVID-19; High flow nasal cannula; Invasive mechanical ventilation; PneumothoraxBarotraumaCOVID-19PneumothoraxInvasive mechanical ventilationAcute respiratory failure
researchProduct

Physiopathological rationale of using high-flow nasal therapy in the acute and chronic setting: A narrative review

2019

Abstract Chronic lung disease and admissions due to acute respiratory failure (ARF) are becoming increasingly common. Consequently, there is a growing focus on optimizing respiratory support, particularly non-invasive respiratory support, to manage these conditions. High flow nasal therapy (HFNT) is a noninvasive technique where humidified and heated gas is delivered through the nose to the airways via small dedicated nasal prongs at flows that are higher than the rates usually applied during conventional oxygen therapy. HFNT enables to deliver different inspired oxygen fractions ranging from 0.21 to 1. Despite having only recently become available, the use of HFNT in the adult population i…

medicine.medical_specialtymedicine.medical_treatmentCritical Care and Intensive Care MedicineAcute respiratory failure03 medical and health sciences0302 clinical medicine030202 anesthesiologyOxygen therapyMedicineAcute respiratory failureRespiratory systemIntensive care medicineNoseHigh flow nasal therapybusiness.industryChronic obstructive pulmonary disease030208 emergency & critical care medicineHigh flow nasal cannulaAnesthesiology and Pain Medicinemedicine.anatomical_structureRespiratory failureLung diseaseNarrative reviewbusinessHigh flowNoninvasive ventilation
researchProduct